Clenbuterol vs HGH Fragment 176-191
Well Studied vs Moderate Research
synergistic Researched · 95% Both target fat loss through complementary adrenergic pathways. The combination may enhance lipolysis beyond either compound alone.
Molecular Data
Clenbuterol HGH Fragment 176-191
Weight 277.19 Da 1,817.1 Da
Half-life ~36 hours 15-20 minutes
Chain — 16 amino acids
Type Sympathomimetic amine (C12H18Cl2N2O) hGH C-terminal fragment (176-191)
Key Benefits
Clenbuterol
01 Increased basal metabolic rate and thermogenesis for accelerated fat loss
02 Preferential mobilization of stored body fat through enhanced lipolysis
03 Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
04 Bronchodilation and improved respiratory capacity during intense exercise
05 Appetite suppression in many users, supporting adherence to caloric deficit
06 Oral administration with no injections required
HGH Fragment 176-191
01 Stimulates lipolysis without growth hormone side effects
02 Does not affect blood glucose or insulin sensitivity
03 Does not increase IGF-1 levels
04 Selectively targets fat metabolism
05 No impact on bone or organ growth
Dosing Protocols
Clenbuterol
20-120 mcg/day / Once daily (morning)
HGH Fragment 176-191
250-500mcg / Twice daily (fasted)
Fat loss - Standard 250mcg Twice daily (morning fasted + pre-bed)
Enhanced fat loss 500mcg Twice daily (morning fasted + pre-bed)
Conservative start 250mcg Once daily (morning, fasted)
Side Effects
Clenbuterol
Tremors and shaking (especially hands) - most pronounced in the first 3-5 days
Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)
Insomnia and sleep disturbance, particularly with afternoon or evening dosing
Muscle cramps (calves, forearms, back) due to taurine depletion
Increased sweating and elevated body temperature
Headaches, particularly during dose ramp-up
Nervousness, anxiety, and restlessness
Increased blood pressure
HGH Fragment 176-191
Injection site irritation (redness, mild swelling)
Headache, particularly in the first few days
Generally well-tolerated with a favorable safety profile
Contraindications
Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia
Uncontrolled hypertension
Hyperthyroidism or thyrotoxicosis
Hypokalemia or electrolyte imbalances
Known hypersensitivity to clenbuterol or sympathomimetic amines
Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors
Pregnancy or breastfeeding
Pregnancy or breastfeeding
Active cancer or history of malignancy
WADA prohibited - athletes subject to testing must avoid
Research Evidence
Clenbuterol HGH Fragment 176-191
Status Well Studied Moderate Research
References 5 studies 4 studies
Latest 2021 2014
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.